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Cellular oxygen sensing is required for hypoxia-inducible fac-
tor-1 stabilization, which is important for tumor cell survival,
proliferation, and angiogenesis. Here we find that terpestacin, a
small molecule previously identified in a screen of microbial
extracts, binds to the 13.4-kDa subunit (UQCRB) of mitochon-
drial Complex III, resulting in inhibition of hypoxia-induced
reactive oxygen species generation. Consequently, such inhibi-
tion blocks hypoxia-inducible factor activation and tumor
angiogenesis in vivo, without inhibiting mitochondrial respira-
tion. Overexpression of UQCRB or its suppression using RNA
interference demonstrates that it plays a crucial role in the oxy-
gen sensing mechanism that regulates responses to hypoxia.
These findings provide a novel molecular basis of terpestacin
targeting UQCRB of Complex III in selective suppression of
tumor progression.
Progression of many solid tumors requires angiogenesis (1).
Mitochondrial function has been linked to angiogenesis,
because mitochondria are the primary sites of oxygen con-
sumption, and angiogenesis is an oxygen concentration-sensi-
tive process (2). Reports suggest that reactive oxygen species
(ROS)3 generation at mitochondrial Complex III is necessary
and sufficient to trigger HIF-1 stabilization during hypoxia,
and cells lacking mitochondrial DNA and electron transport
activity ( cells) fail to exhibit increased ROS or up-regulation
of HIF-1 target genes during hypoxia (3–5). Inhibitors of
Complex III such as myxothiazol and stigmatellin also block
mitochondrial ROS generation and inhibit the stabilization and
transcriptional activity of HIF-1 during hypoxia. These find-
ings suggest that the generation of ROS from mitochondrial
Complex III is a critical event in the signaling of cellular hypoxia
(6, 7). However, details regarding which of the components of
Complex III contribute to this signaling remain to be described.
Biological screening tools are useful for identifying naturally
occurring small molecules capable of inducing a specific
phenotype change (8, 9). We performed a large scale screen
of microbial extracts in an attempt to identify small molecules
that could inhibit the angiogenic response to pro-angiogenic
stimuli, such as hypoxia, in endothelial cells. We identified
terpestacin as a small molecule with unique bicyclo sesterter-
pene structure capable of inhibiting the angiogenic response at
concentrations below the toxic threshold (10). Terpestacin
strongly inhibits the functional response to hypoxia of human
umbilical vein endothelial cells in vitro and angiogenesis within
the embryonic chick chorioallantoicmembrane in vivo. In addi-
tion to this anti-angiogenic activity, terpestacin has previously
been reported to inhibit syncytium formation during human
immunodeficiency virus infection and has been chemically syn-
thesized (11–13). However, neither the molecular target of this
compound nor the cellular mechanism of its anti-angiogenic
activity has been identified.
In the present study we identified the binding protein of
terpestacin and clarified the cellular mechanism underlying
its effects on angiogenesis. We find that terpestacin specifi-
cally binds to the 13.4-kDa subunit (UQCRB in human; acces-
sion number NM_006294; QCR7 in yeast; Sub 6 in bovine or
chicken) of Complex III in the mitochondrial respiratory chain
(14). The biological activity of terpestacin correlates signifi-
cantly with the response to UQCRB knockdown inmammalian
cells. The discovery that a small molecule targeting UQCRB in
mitochondrial Complex III can prevent the angiogenic re-
sponse in vivo and in vitro without inducing cell death implies
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that UQCRB plays a key role in the cellular oxygen sensing and
transduction system. This study provides new insight into the
oxygen sensing role of UQCRB in mitochondrial Complex III,
and a small molecule targeting that system provides a powerful
tool for regulating tumor angiogenesis.
EXPERIMENTAL PROCEDURES
In Vivo Breast Cancer Xenograft Model Study—Twenty-four
C3H/HeJmice were inoculated subcutaneously with spontane-
ously occurring FM3A breast cancer cells. Twelve mice were
treated intraperitoneally with terpestacin (2.5 M) on days 0, 2,
4, 6, and 8. Another twelve mice were injected with saline as a
negative control. On day 10, the tumor-bearing mice were
examined with dynamic T1-weighted sequences using gad-
olinium diethylenetriaminepentaacetate in a 1.5T magnetic
resonance (MR) scanner. After examination, the tumors were
harvested for immunostaining of tumor blood vessels and
expression of hypoxia-responsible genes, HIF-1, and VEGF.
MRI—MRIwas performed on a clinical 1.5 Twhole bodyMR
system (Gyroscan, Philips) using a custom-made radiofre-
quency coil for excitation and signal reception. All of the ani-
mals were examined with high resolution T1- and T2-weighted
pulse sequences and dynamic contrast-enhanced T1-weighted
MRI using the following imaging parameters: repetition time/
echo time (TR/TE) 500/10 ms, flip angle 30°, acquisition
8, matrix size  256  198, slice thickness  1.5 mm, and
in-plane resolution 234 234 m.
Immunohistochemistry—Five-micrometer paraffin sections
were incubated with anti-CD34 (Santa Cruz), anti-HIF-1
(Novus), and anti-VEGF (R & D Systems) mouse monoclonal
antibodies for 1 h, respectively. After rinsing, the slides were
incubated with secondary antibody for 45 min. The LSAB2/
HRP staining kit (DakoCytomation) and the En Vision kit
(DakoCytomation) were used for secondary antibody reaction.
The slides were then washed and incubated with an avidin-
biotin-peroxidase complex, followed by 3,3-diaminobenzidine
tetrahydrochloride color development. Counterstaining was
performed using hematoxylin.
VEGF-Enzyme-linked Immunosorbent Assay—C3H mice
with FM3A breast carcinomas were injected with either terpes-
tacin or vehicle (saline) at 2-day intervals. The implants were
harvested on day 7, and the concentration of VEGF protein in
tumor tissue extracts was determined by a VEGF-enzyme-
linked immunosorbent assay (R & D Systems) according to the
manufacturer’s instructions. VEGF protein levels were normal-
ized to the total protein concentration of each sample.
Synthesis of Molecular Probes for Terpestacin—Biotinylated
terpestacin with 1-ethyl-3-[3-dimethylaminopropyl] carbodi-
imide hydrochloride (1.5mg, 0.0078mmol) anddimethylamino-
pyridine (1.0 mg, 0.0082 mmol) were added to a stirred
solution of terpestacin (3.0 mg, 0.0075 mmol) and N-()-biotinyl-
6-aminohexanoic acid (2.7 mg, 0.0076mmol; Pierce) inMe2SO
(3 ml) was added at 0 °C. After incubation overnight at room
temperature, the crude product was extracted with EtOAc (15
ml) and purified by preparative TLC (CH2Cl2:methanol 10:1)
to yield two biotinylated terpestacin derivatives (hydroxyl
group at the C-24 position (BT1) and hydroxyl group at the
C-17 position (BT2)). This procedure resulted in 75% yield. The
matrix-assisted laser desorption ionization-mass spectrometry
value for C41H63N3O7S wasm/z 764.5 [M Na].
Coumarin-conjugated Terpestacin—1-Ethyl-3-[3-dimethyl-
aminopropyl] carbodiimide hydrochloride (1.0 mg, 0.0052
mmol) and dimethylaminopyridine (0.64 mg, 0.0052 mmol)
were added to a stirred solution of terpestacin (2.0 mg, 0.005
mmol) and Boc-6-aminohexanoic acid (1.2 mg, 0.0052 mmol)
in dimethylformamide (2 ml) at 0 °C. After incubation over-
night at room temperature, the crude product was extracted
with EtOAc (4 ml 3), treated with 20% trifluoroacetic acid
in CH2Cl2 (1 ml), and stirred for 2 h at room temperature.
N,N-diisopropylethylamine (1.3 mg, 0.01 mmol) and 6-((7-
amino-4-methylcoumarin-3-acetyl) amino) hexanoic acid
succinimidyl ester (2.2 mg, 0.005 mmol, Molecular Probes)
were added at 0 °C. After stirring for 4 h at room tempera-
ture, the crude product was extracted with EtOAc (20 ml)
and purified by preparative TLC (CH2Cl2:methanol 10:1) to
produce coumarin-conjugated terpestacin at 61% yield.
Matrix-assisted laser desorption ionization-mass spectrometry
for C49H71N3O9 m/z 868.5 [M Na].
Phage Display Affinity Selection—Biotinylated terpestacin
was immobilized onto a streptavidin-coated plate (Pierce), and
phage display was performed using T7 phages encoding human
cDNA libraries from liver tumor, normal liver, Alzheimer’s
brain, normal brain, and normal stomach tissues (Novagen)
as described previously (15). Specific terpestacin-binding
phages were isolated and analyzed by DNA sequencing using
the PRISM dye terminator cycle sequencing ready reaction
kit (Applied Biosystems). The sequence homologies of the
obtained sequences were compared with sequences in
GenBankTM using the BLAST program.
Molecular Cloning, Expression, and Purification of Human
UQCRB—For mammalian expression, the full-length human
UQCRB expression vector was constructed by subcloning a
PCR-amplified full-length cDNA of UQCRB (accession num-
ber NM_006294) into the EcoRI/XhoI site of pCDNA3.1-HA
(Invitrogen). To obtain the recombinant UQCRB protein from
bacteria, the UQCRB cDNA was inserted into the EcoRI/XhoI
site of pGEX-4T1 (Amersham Biosciences). The glutathione
S-transferase-UQCRB fusion protein was purified as described
previously (16) and treated with thrombin (Amersham Bio-
sciences) for the removal of glutathione S-transferase.
Site-directed Mutagenesis—The QuikChange site-directed
mutagenesis system (Stratagene) was used to mutate selected
codons in the clone of human UQCRB gene. The following
primers were used: to change Leu32 to Ala, 5-GCAGGATTC-
AATAAACTGGGGGCAATGCGAGATGATACA-3 and 5-
TGTATCATCTCGCATTGCCCCCAGTTTATTGAATC-
CTGC-3; and to change Ile63 to Ala, 5-AATGACAGGAT-
GTTTCGCGCTAAGAGGGCACTGGAC-3 and 5-GTCC-
AGTGCCCTCTTAGCGCGAAACATCCTGTCATT-3. The
mutated codons are underlined. PCR was performed under the
following conditions: initial denaturation for 30 s at 95 °C, 16
cycles of 30 s at 95 °C, 1 min at 55 °C, and 12min at 68 °C. After
digestion of the parental DNA for 1 h at 37 °C with DpnI, the
amplified plasmidswere transformed intoEscherichia coliXL-1
Blue competent cells. The presence of the mutation was con-
firmed by DNA sequencing.
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Surface Plasmon Resonance (SPR) Analysis—Biotin and bio-
tinylated terpestacin were sequentially immobilized on the sur-
face of a streptavidin-coated sensor chip.Molecular interaction
analysis was performed using the BIAcore 2000 (BIAcore AB)
as described previously (15). The SPR response curves were
analyzed with BIAcore Evaluations software, version 3.1.
The apparent association and dissociation constants were cal-
culated from the kinetic constants equations:KA ka/kd,KD
kd/ka.
Docking Simulation—The structure of terpestacin was opti-
mized employing the nonlocal density functional theory
(B3LYP DFT) function and restricted Hartree-Fock (RHF)/6–
31G(*) basis set description. All of the atomic charges were
assigned using the Mullikan Populations of Gaussian 03 calcu-
lation result. To find out the docking structures of terpestacin
into UQCRB, automated docking simulation was implemented
with the programAutoDock version 3.0. TheUQCRB structure
was used for x-ray crystal structure from the Protein Data Bank
(code 3BCC; chicken cytochrome bc1 complex). An initial pro-
tein structure was energy minimized for 1000 steps employing
the steepest descent algorithm. In AutoDock, docking was per-
formed by combining a global genetic algorithmwith localmin-
imization, Lamarckian genetic algorithm. 100 trials of each
docking were preformed, and final docked conformations were
clustered using a tolerance of 1 Å root mean square deviation.
The docking conformation properly oriented toward the
UQCRBpocket was selected, and the free energy of bindingwas
estimated.
Subcellular Localization Analysis of Terpestacin—For fluo-
rescence microscope analysis, HT1080 cells were incubated
with 20 M of coumarin or coumarin-conjugated terpestacin
(ter-coumarin) for 24 h in the presence or absence of excess
terpestacin. After washing with phosphate-buffered saline,
the cells were observed under a fluorescence microscope
(Olympus). To determine the subcellular localization of ter-
pestacin, HT1080 cells were grown on glass coverslips in
24-well plates and treated with 50 M of coumarin or ter-cou-
marin for 30 min. To stain the mitochondria, the cells were
treated with MitoTracker (100 nM, catalog number M-7512;
Molecular Probes) at 37 °C for 15 min. After washing with
phosphate-buffered saline, the cells were fixed with 4% formal-
dehyde, and the coverslips were mounted with a ProLong anti-
fade kit (Molecular Probes) according to the manufacturer’s
instructions. The fluorescence image was obtained using a con-
focal laser scanning microscope (Axiovert 100M; Carl Zeiss).
Transcriptional Profiling—Total RNA was prepared from
HT1080 cells using the TRIzol reagent (Invitrogen). The
probe preparation and microarray hybridization was per-
formed using the TwinChip Human-8K cDNA microarray
(Digital Genomics) as described previously (17). Microarray
data analysis was conducted using the GeneSight data analysis
software (v3.5, BioDiscovery). Signature correlation coefficient
values () between two experimental conditions were obtained
as described previously (18).
Measurement of Mitochondrial Membrane Potential (m)—
The change in m was detected by a fluorescence-based
assay. The cells were incubated for 4 h with radicicol or terpes-
tacin and then stained for 15 min with 0.25 g/ml of 5,5,6,6-
tetrachloro-1,1,3,3-tetraethylbenzimidazol-carbocyanine
iodide, which is a lipophilic cationic probe (JC-1; Molecular
Probes). At hyperpolarized membrane potentials (to 140
mV), this dye forms a red fluorescent J-aggregate, whereas at
depolarized membrane potentials (to 100 mV), this dye
remains in its green fluorescent monomeric form. Subse-
quently, the cells were washed with phosphate-buffered saline
twice. The images were obtained using an IX70 fluorescence
microscope (Olympus) at a100 magnification.
Measurement of Mitochondrial Oxygen Consumption—Mi-
tochondrial respiration was measured using succinate, a sub-
strate for Complex II. When succinate (5 mM) was added to
mitochondria, the flavin adenine dinucleotide-linked O2 con-
sumption was stimulated. Mouse liver mitochondria (0.2
mg/ml) were pretreated for 15minwith terpestacin (80g/ml),
antimycin A (0.1 g/ml), or methanol control (0.5%). The res-
piration rate of mitochondria was measured with Clark-type
oxygen electrode (Oxygen electrode Units DW1; Hansatech
Instruments) at 30 °C.
Cell Culture and Hypoxic Condition—Early passages (4–8
passages) of HUVECswere grown in endothelial cell medium-2
(EGM-2, Cambrex) supplemented with 10% fetal bovine serum
(Invitrogen). HT1080 (fibrosarcoma) cells were maintained in
minimum essential medium (Invitrogen) containing 10% fetal
bovine serum. 143B (osteosarcoma), HepG2 (hepatoma), HeLa
(cervical squamous carcinoma), CHANG (normal liver), and
Hep3B (hepatoma) cells were grown in Dulbecco’s modified
Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum. All of the cells were maintained in a humidified
5% CO2 incubator. For the hypoxic conditions, the cells were
incubated at a CO2 level of 5% with 1% O2 balanced with N2 in
a hypoxic chamber (Forma).
Western Blot Analysis—The cell lysates were separated by
10% SDS-PAGE and were then transferred to polyvinylidene
fluoride membranes (Milipore) using standard electroblotting
procedures. The blots were then blocked and immunolabeled
overnight at 4 °C with anti-HIF-1 (BD Biosciences), anti-
VEGF (Santa Cruz), anti-phospho-p70S6K (Cell Signaling),
anti-p70S6K (Cell Signaling), anti--actin, and anti-tubulin
(Upstate Biotechnology Inc.) primary antibodies. Immunola-
beling was detected by an ECL kit (Amersham Biosciences)
according to the manufacturer’s instructions.
Measurement of ROS—Intracellular ROS levels were mea-
sured using 2,7-dichlorofluorescein diacetate (Sigma). ROS in
the cells cause oxidation of 2,7-dichlorofluorescein, generat-
ing a fluorescent product, 2,7-dichlorofluorescein. After incu-
bation with 2,7-dichlorofluorescein diacetate (10 M) for 10
min, the cells were lysed and centrifuged to remove debris. The
fluorescence in the protein-normalized supernatant was deter-
mined using a FL600 microplate fluorescence reader (Bio-Tek)
at the excitation and emission wavelengths of 485 and 535 nm,
respectively.
Overexpression and RNA Interference Studies of UQCRB—
For UQCRB overexpression, HT1080 cells were transfected
with either control (neo) or UQCRB expression vectors (1 g)
using the SuperFect transfection reagent (Qiagen). Human
UQCRB-specific siRNA was constructed using the StealthTM
RNA interference (Invitrogen). For the knockdown of UQCRB
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mRNA, HT1080 cells were transfected with either control or
UQCRB siRNA (5, 10 nM) using the LipofectamineTM 2000
transfection reagent (Invitrogen) according to the manufactur-
er’s instructions. Interference of UQCRB mRNA was validated
though reverse transcription-PCR analysis using specific prim-
ers for UQCRB.
In Vitro Invasion and Angiogenesis Assays—The invasiveness
of endothelial or tumor cells was examined using a Transwell
chamber system with 8.0-m pore-sized polycarbonate filter
inserts (Corning Costar). The total number of invaded cells was
counted using an optical microscope at a100 magnification.
The tube formation assaywas conducted usingHUVECs grown
on Matrigel as described previously (10). Tube formation was
quantified by counting the number of connected cells in ran-
domly selected fields at a100magnification and dividing that
number by the total number of cells in the same field.
Materials—Terpestacinwaspurified fromthe culture extract of
a fungal strain,Embellisia chlamydospora, as described previously
(10). Antimycin A, myxothiazol, and rotenone were purchased
from Sigma, and stigmatellin was purchased from Fluka.
Statistical Analysis—The results are expressed as the
means S.E. The Student’s t test was used to determine statis-
tical significance between control and test groups. A p value of
	0.05 was considered statistically significant.
RESULTS
Identification of Human UQCRB as a Terpestacin-binding
Protein—To explore the molecular mechanisms underlying
inhibition of angiogenesis by terpestacin, phage display biopan-
ning, an approach that has proven to be a powerful means to
identify cellular binding proteins of bioactive small molecules,
was applied to identify terpestacin binding proteins (15, 19).
Terpestacin was biotinylated at either the C-24 (BT1) or C-17
(BT2) position hydroxyl group to produce an affinity ligand for
the isolation of its binding proteins (Fig. 1A). Both BT1 andBT2
retained their biological activity, as shown by their anti-prolif-
erative activities in HUVECs. BT1 was first immobilized on a
streptavidin-coated well plate, and four rounds of phage bio-
panningwere conducted usingT7phages expressing functional
human cDNA libraries (6  109 phage plaque-forming unit/
ml). After the fourth round of biopanning, phage particles that
bound specifically to BT1 were isolated and analyzed by DNA
sequencing (Fig. 1B). Among a total of 18 phage plaques iso-
lated for DNA sequencing, all phage clones (100%) were iden-
tified as human UQCRB-encoding phages (Fig. 1C). An inde-
pendent experiment was performed using BT2 affinity ligand
using the same procedure as for BT1. As the result, more than
90% (18 of a total of 20 phage clones) of BT2-binding phages
were expressing UQCRB. The remaining BT2-binding phage
clones were found to represent nonspecific binders (Fig.
1D). The highly enriched biopanning result of phage display
with two biotinylated terpestacins strongly demonstrate that
UQCRB is the highest affinity binding protein of terpestacin.
Analysis of the Molecular Interaction between Terpestacin
and UQCRB—To verify the specific binding of terpestacin to
UQCRB, a phage display binding assay was investigated first
with diverse classes of biologically active small molecules. The
FIGURE 1. Identification of terpestacin-binding protein using phage display affinity selection. A, the structures of terpestacin and themolecular probes,
including coumarin-conjugated terpestacin (ter-coumarin) and the biotinylated terpestacin derivatives (BT1 for C-24 position and BT2 for C-17 position of
hydroxyl groups). B, analysis of the number of terpestacin-binding phages eluted after each round of biopanning (Elute).Wash indicates nonspecific phages
bound to biotinylated terpestacin immobilized onto streptavidin-coated wells. Pfu, phage plaque-forming unit. C, coding region of terpestacin-binding
phages of human full-length UQCRB. D, the specificity of the interaction between BT2 and UQCRB-expressing phages. Control biotin and nonspecific phages
(N1 and N2) were used as negative controls for BT2 and UQCRB phage, respectively. *, p	 0.001 versus control biotin. Each value represents the mean S.E.
from three independent experiments.
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binding of UQCRB-encoding phages to BT1 was completely
abolished in the presence of excess free terpestacin but was not
influenced by othermitochondrial inhibitors or by other angio-
genesis inhibitors (Fig. 2A), implying that terpestacin specifi-
cally binds to UQCRB and is the first small molecule targeting
UQCRB.
Next, the interaction between terpestacin and intact human
UQCRB was demonstrated by surface plasmon resonance
(BIAcore) analysis. The apparent binding affinities were calcu-
lated by subtraction of resonance values of UQCRB binding to
control biotin from those of UQCRB binding to BT1. This anal-
ysis yielded specific binding curves forUQCRB to BT1 from the
BIAcore sensorgrams, and the apparent dissociation constant
(KD) of UQCRB binding to terpestacin was calculated as 3.1
106 M (Fig. 2B). These results clearly demonstrate that
UQCRB is a direct binding protein of terpestacin atmicromolar
levels close to its effective concentration toward the anti-angio-
genic activity (5–10 M).
Next, the interaction between terpestacin andUQCRB in the
cellular level was assessed on the basis of the subcellular local-
ization of ter-coumarin as a probe. Indeed, ter-coumarin inten-
sively stains the cytoplasmic part ofHT1080 fibrosarcoma cells,
whereas control coumarin does not (Fig. 2C,upper panels). Pre-
treatment with excess free terpestacin in the cells dose-depen-
dently decreased the fluorescence intensity of ter-coumarin,
demonstrating that the probe specifically binds to the terpesta-
cin target proteins in the cells. Furthermore, confocal micros-
copy analysis using ter-coumarin and a mitochondrial specific
marker, MitoTracker, revealed the fluorescence signal of ter-
coumarin coincided exactly with that of MitoTracker (Fig. 2C,
lower panels), implying again that terpestacin binds to mito-
chondria in the cells where its target, UQCRB, is located.
To further elucidate the binding mode of terpestacin to
UQCRB at molecular level, we simulated a binding model of
UQCRB with terpestacin using the reference protein (Protein
Data Bank code 3BCC; chicken cytochrome bc1 complex) (20)
and the AutoDock program. The docking modeling revealed
that terpestacin binds to the hydrophobic pocket of UQCRB via
its large hydrophobic ring structure, and nonpolar amino acid
residues, including Leu32 and Ile63 of UQCRB, appear to be
crucial for the hydrophobic interaction (Fig. 3, A and B). In
addition, this model showed that terpestacin binds to the inter-
face of the binding site between UQCRB and cytochrome b,
suggesting that terpestacin could affect the interaction between
cytochrome b and UQCRB. To verify this binding model of
terpestacin and UQCRB, we constructed UQCRB mutants
including L32A, I63A, and L32A/I63A and examined the bind-
ing affinity of thesemutants to terpestacin by SPR analysis. The
binding efficiency of L32A and I63A to terpestacin was
decreased to 65 and 25%, respectively (Fig. 3C). Notably, the
combined mutant of L32A and I63A completely abolished the
binding with terpestacin. Bovine serum albumin as a nega-
tive control did not bind to terpestacin. These results validate the
binding model that represents the significance of hydrophobic
amino acid residues of UQCRB for the binding to terpestacin.
In addition, the functional genomic consequences of terpes-
tacin binding to UQCRB was investigated by using cDNA
microarray analysis of transcriptional changes in HT1080 cells
treated with terpestacin or siRNA directed against human
UQCRB (siUQCRB). The genome-wide gene expression profil-
ing showed a significant correlation between terpestacin and
UQCRB genetic knockdown, validating that UQCRB is a bio-
logically relevant target of terpestacin (supplemental Fig. S1).
All of these in vitro and in vivo data strongly demonstrate that
UQCRB of mitochondrial Complex III is a cellular target pro-
tein of terpestacin and suggest a critical role for UQCRB in
angiogenesis.
Terpestacin Decreases the Mitochondrial Membrane Poten-
tial (m) without Inhibiting Mitochondrial Respiration—
Next, we investigated the biological implication of the binding
of terpestacin toUQCRB. To elucidate whether this interaction
causes mitochondrial dysfunction, the mitochondrial mem-
brane potential (m)wasmeasured using the JC-1 fluorescent
marker. As shown in Fig. 4A, control HT1080 cells or cells
FIGURE2.Molecular interactions and subcellular localizationof terpesta-
cin. A, effects of various competitors on the binding between UQCRB phages
and immobilized terpestacin. All of the competitors were used at a concen-
tration of 100 M. Ter, terpestacin; Ant, antimycin A; Myx, myxothiazol; Stig,
stigmatellin; Rot, rotenone; BetA, betulinic acid; Rad, radicicol; Cur, curcumin;
Cel, celecoxib; SAHA, suberoylanilide hydroxamic acid; Pfu, phage plaque-
forming unit. *, p	 0.001 versusno competitor control. Each value represents
the mean S.E. from three independent experiments. B, SPR analysis of the
interaction between terpestacin and purified recombinant UQCRB at various
concentrations. The results shown are representative of three independent
experiments. C, binding of ter-coumarin (20M) to a specific target in cells in
the presence of excess terpestacin (30 or 40 M) through a fluorescence
microscope (upper panels). Scale bar, 200m. Colocalization of ter-coumarin
(blue) andMitoTracker (red) using a confocal microscope (lower panels). Scale
bar, 20 m. The results shown are representative of three independent
experiments.
Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB
11588 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 15•APRIL 9, 2010
treated with radicicol, a structurally related molecule targeting
heat shock protein 90 (Hsp90), exhibited a low level of green
fluorescence and a high red-orange fluorescence (large negative
m). However, treatment with terpestacin led to an increase
in green fluorescence and a decrease in red-orange fluorescence
in a dose-dependentmanner (loss ofm). These data demon-
strate that the binding of terpestacin to UQCRB results in a
mitochondrial response involving a dissipation of the mito-
chondrial membrane potential.
To further examine whether the binding of terpestacin to
UQCRB affects mitochondrial energy metabolism, the mito-
chondrial oxygen consumption was measured using mouse
liver mitochondria and succinate, a substrate for Complex II.
As shown in Fig. 4B, mitochondrial respiration was strongly
inhibited by antimycin A, whereas terpestacin did not inhibit
oxygen consumption generated by the oxidation of succinate,
implying that terpestacin regulates the function of mitochon-
drial Complex III without disrupting respiration, making it
likely that ATP generation is not affected.
Terpestacin Suppresses Mitochondrial ROS Generation and
HIF-1 Stabilization under Hypoxic Conditions—Mitochon-
drial Complex III is a major site of cellular ROS generation
during hypoxia and is known to be involved in cellular oxy-
gen sensing (5). Moreover, the increase in ROS production
during hypoxia has been reported to initiate the stabilization
of HIF-1 protein and to mediate hypoxia-induced transcrip-
tion of genes such asVEGF (4). To examinewhether terpestacin
affects Complex III-derived ROS generation during hypoxia,
FIGURE 3.Dockingmodel of terpestacin-UQCRB complex. A, electrostatic surface representation of the hydrophobic pocket of UQCRB bound with terpes-
tacin. The red color denotes electronegative charge potential, and the blue color denotes electropositive charge potential. B, docking model analysis of
terpestacin (red) and UQCRB (blue). The dotted circles indicate hydrophobic interaction of the complex. C, SPR analysis of the interaction between terpestacin
andUQCRBwild andmutants. Thebindingefficiencyofwild type (WT) UQCRB to terpestacinwasdefinedas 100%. #,p	0.03; ##,p	0.01; ###,p	0.007 versus
WT UQCRB. Each value represents the mean S.E. from three independent experiments.
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we assessed intracellular ROS levels in HT1080 cells using the
oxidant-sensitive fluorescent probe, 2,7-dichlorofluorescein.
Terpestacin significantly suppressed the hypoxia-induced ROS
generation inHT1080 cells (Fig. 5A). However, antimycin A, an
inhibitor of downstream end of Complex III, did not elicit a
decrease in ROS generation during hypoxia.
HIF-1 stabilization represents a functional response to
hypoxia triggered by the cellular oxygen sensing system. We
investigated the effect of terpestacin on HIF-1 stabilization
to assess its influence on the cellular response to hypoxia.
Hypoxia-induced accumulation of HIF-1 protein was dose-
dependently inhibited by terpestacin (Fig. 5B). The HIF-1
destabilizing activity of terpestacin during hypoxia was ver-
ified in a number of animal cell lines as well (supple-
mental Fig. S2). To clarify that terpestacin affects HIF-1
stability induced by hypoxia, we next performed time course
experiments of HIF-1 accumulation in the presence of terpes-
tacin before or after hypoxia. As shown in Fig. 5C, terpestacin
treatment before as well as after hypoxia expose effectively
inhibited HIF-1 accumulation, implying that the HIF-1
destabilizing activity of terpestacin results from the suppres-
sion of ROS generation induced by hypoxia. To further verify
whether terpestacin inhibits the stabilization ofHIF-1 via sup-
pression of Complex III-derived ROS generation, the effect
of terpestacin on desferrioxamine-induced accumulation of
HIF-1 proteinwas investigated. Previous reports revealed that
the iron chelator desferrioxamine induces HIF-1 stabilization
but does not requiremitochondrial ROS (4). Terpestacinmark-
edly inhibited the stabilization of
HIF-1 during hypoxia but not dur-
ing desferrioxamine treatment (Fig.
5D), demonstrating that terpestacin
inhibits the stabilization of HIF-1
by suppressing mitochondrial ROS.
Next, we examined whether ter-
pestacin-mediated inhibition of
HIF-1 accumulation is associ-
ated with altered HIF-1 protein
synthesis. MG132, a specific pro-
teasome inhibitor, was used to block
ubiquitin-dependentHIF-1 degra-
dation. As expected, treatment with
MG132 resulted in a marked accu-
mulation of ubiquitinated HIF-1
proteins during hypoxia (Fig. 5E).
By contrast, the inhibition of pro-
tein synthesis with cycloheximide
blocked the accumulation of HIF-1
induced by hypoxia. Treatment with
terpestacin under hypoxia in the
presence ofMG132 led to a substan-
tial reduction of ubiquitinylated
HIF-1 protein, suggesting that ter-
pestacin may affect the upstream
step of HIF-1 protein degradation
by ubiquitin-proteasome pathway.
In addition, the compound inhib-
ited the phosphorylation of p70S6K,
a downstream effector of phosphoinositide 3-kinase/Akt/
mammalian target of rapamycin pathway that is implicated in
the regulation of HIF-1 expression at the translational level
(Fig. 5F) (21, 22). However, terpestacin did not affect mRNA
level of HIF-1, suggesting that the reduction of HIF-1 pro-
tein level by terpestacin is not due to the transcriptional reduc-
tion of HIF-1 gene (Fig. 5G). Moreover, terpestacin alone
exhibited a much higher reduction of HIF-1 protein than that
of MG132 in combination under hypoxic conditions, suggest-
ing that terpestacin may inhibit both protein synthesis and sta-
bility of HIF-1 through suppression of Complex III-derived
ROS generation during hypoxia.
Terpestacin Inhibits Hypoxia-induced Tumor Angiogene-
sis in an Animal Model System—HIF-1 plays a crucial role
in tumor angiogenesis through the up-regulation of its angio-
genic transcription products.We thus investigated the effect of
terpestacin on tumor angiogenesis in a murine breast carci-
noma xenograft model. C3H/HeJ mice were inoculated with
spontaneously occurring FM3A breast cancer cells, and the
mice were treated with or without terpestacin intraperitone-
ally. The tumor-bearing mice were examined with dynamic
T1-weighted sequences using gadolinium diethylenetriamine-
pentaacetate in a 1.5T MR scanner. The MR amplitude, which
reflects plasma volume, and the Kep parameter, which is influ-
enced by the vessel permeability, were calculated using a two-
compartment model. The resulting MR signal intensity was

3-fold weaker in mice treated with terpestacin than in the
saline control at the 900-s time point (Fig. 6A), indicating that
FIGURE 4. Effects of terpestacin onmitochondrial membrane potential (m) andmitochondrial respi-
ration. A, HT1080 cells were incubated for 4 h with terpestacin (Ter, 20 or 50 M) or radicicol (Rad, 10 M) and
then stained with 0.25 g/ml of JC-1 for 15 min. Fluorescence images were obtained with a fluorescence
microscope. Scale bar, 200 m. The results shown are representative of three independent experiments.
B, mouse liver mitochondria (0.2 mg/ml) were pretreated for 15 min with terpestacin (80 g/ml), antimycin A
(0.1 g/ml), or methanol control (Con, 0.5%). The respiration rate of mitochondria was measured with Clark-
type oxygen electrode at 30 °C. The results shown are representative of two independent experiments.
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terpestacin efficiently inhibits the formation of blood vessels
within the tumor.
After examination, the tumors were harvested for immuno-
staining of tumor blood vessel density using an anti-CD34 anti-
body. High blood vessel density was observed in control tumor
tissues, whereas a significant decrease in the vessel density was
observed in the animals treated with terpestacin (Fig. 6B).
These data demonstrate that terpestacin effectively inhibits
tumor angiogenesis in vivo.
VEGF is a major target gene of HIF-1 and plays a critical
role in hypoxia-induced angiogenesis. We therefore examined
the effect of terpestacin onHIF-1 and VEGF expression in the
murine breast carcinoma xenograft model by immunohisto-
chemical staining. In saline control tumors, many blood vessels
were found, and HIF-1 and VEGF were highly expressed (Fig.
6C). However, HIF-1 and VEGF expression as well as blood
vessel formation were markedly reduced in terpestacin-treated
tumors. Moreover, compared with controls, terpestacin signif-
icantly decreased VEGF protein levels in the mouse tumor tis-
sue extracts (Fig. 6D). These data indicate that terpestacin
inhibits hypoxia-induced tumor angiogenesis via the inhibition
of HIF-1-mediated VEGF expression.
Implication of UQCRB in Hypoxia-induced Angiogenesis—
As inferred from the results of the biological activity of ter-
pestacin, UQCRB may play an important role in modulating
the ROS- and HIF-mediated angiogenesis during hypoxia. To
elucidate the role of UQCRB in angiogenesis, we conducted
both UQCRB overexpression and knockdown experiments in
HT1080 cells, and the resulting phenotypes were analyzed.
First, HT1080 cells were transiently transfected with a vector
containing the full-length UQCRB gene or control and exam-
ined for their invasive potential under normoxic conditions.
Overexpression of UQCRB in HT1080 cells significantly
increased the invasion of the tumor cells under normoxia (Fig.
7A). To examine the involvement of ROS in the promotion of
tumor cell invasion by UQCRB, the intracellular ROS level
was measured using 2,7-dichlorofluorescein fluorescence
analysis. Increased 2,7-dichlorofluorescein fluorescence was
FIGURE 5. Effects of terpestacin on mitochondrial ROS generation and HIF-1 stability. A, intracellular ROS levels were determined by the 2,7-dichlo-
rofluorescein (DCF) fluorescence. HT1080 cells were pretreated with terpestacin (Ter, 30 M) or antimycin A (10 M) for 30 min and then exposed to 1% O2for
2 h.Nor, normoxia;Hyp, hypoxia. ##, p	 0.01 versus normoxic control; ***, p	 0.005 versus hypoxic control. Each value represents themean S.E. from three
independent experiments. B, HIF-1 protein levels were analyzed usingWestern blot analysis. The cells were pretreated with terpestacin for 30min and then
exposed to 1%O2 for 4 h (upper panel). Western blot datawere quantitated using densitometry (lower panel). **, p	 0.002; *, p	 0.001 versus hypoxic control.
Each value represents the mean S.E. from three independent experiments. C, HIF-1 protein levels in cells exposed to 1% O2 for the indicated times in the
absence (NT, not treatedwith terpestacin) or presence of terpestacin (50M, before (P) or after (S) hypoxia expose). The cells were pretreatedwith terpestacin
for 30minand thenexposed to1%O2(P). The cellswereexposed to1%O2and simultaneously treatedwith terpestacin (S). The results shownare representative
of three independent experiments.D, HIF-1 protein levels in cells exposed to 1%O2 or desferrioxamine (DFO, 100M) for 4 hwith orwithout terpestacin. The
level of -actin was used as an internal control for normalization. The results shown are representative of three independent experiments. E, cells were
incubated for 2 h under hypoxic conditions. The cells were then treated for additional 1 h under the same atmospheres in the presence of MG132 (20 M),
cycloheximide (CHX, 100 M), or terpestacin (50 M). The results shown are representative of two independent experiments. F, effect of terpestacin on the
phosphorylation of p70S6K. The cells were incubated for 30 min in hypoxia in the presence of terpestacin (50 M) or LY294002 (LY, 20 M). The results shown
are representative of three independent experiments. G, cells were pretreated with terpestacin (40 and 80 M) for 30 min and then exposed to 1% O2 for 4 h.
HIF-1mRNA levels were determined by quantitative PCR.
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observed inUQCRB transfected cells under normoxia (Fig. 7B).
Notably, terpestacin, but not antimycin A, dose-dependently
inhibited the UQCRB-induced ROS generation in HT1080
cells. Moreover, overexpression of UQCRB slightly, but repro-
ducibly, increased the protein stability of HIF-1 under nor-
moxia (Fig. 7C). An increase in the HIF-1 stability during
UQCRB overexpression was comparable with that induced by
cobalt chloride treatment, which has been shown to mimic the
transcriptional response to hypoxia by inhibiting HIF-1 deg-
radation. Expression of VEGF was also increased by UQCRB
overexpression in HT1080 cells under normoxia (Fig. 7D).
However, expression of VEGF receptors, such as Flt-1 and
KDR,was not significantly changed byUQCRBoverexpression.
Second, we investigated the effect of siUQCRB on the angio-
genesis promoting potential of HT1080 cells under hypoxia.
HT1080 cells were transfected with either siUQCRB or control
siRNA and incubated in a hypoxic chamber. Knockdown of
UQCRB gene by siUQCRB was confirmed through reverse
transcription-PCR analysis (Fig. 7E). We first investigated the
effect of UQCRB knockdown on the HIF-1 protein stability
and VEGF expression in HT1080 cells. Hypoxia strongly
increased both the protein stability of HIF-1 and the level of
VEGF in HT1080 cells (Fig. 7F). These hypoxic effects were
significantly blocked by UQCRB knockdown. Next, the con-
ditioned media from the HT1080 cells incubated in each
culture condition were collected and subjected to in vitro
angiogenesis assays. The condi-
tioned media from HT1080 cells
incubated in the hypoxic chamber
strongly activated the invasion and
tube formation of HUVECs (Fig.
7G). However, the conditioned
media from siUQCRB transfected
HT1080 cells completely blocked the
hypoxia-induced tumor angiogenesis
of HUVECs. These data strongly
demonstrate that UQCRB in mito-
chondrial Complex III is a critical
mediator of hypoxia-induced tumor
angiogenesis via ROS-mediated sig-
naling originating from amitochon-
drial O2 sensor.
DISCUSSION
The present study reveals a novel
role ofUQCRBof themitochondrial
Complex III as a component of an
oxygen sensor, through the identifi-
cation of the protein target and the
mode of action of a unique small
molecule probe, terpestacin. Target
validation was conducted using a
number of biophysical, cell biologi-
cal, and genome-wide transcrip-
tional profiling of cells treated with
the drug or subjected to genetic
knockdown. Collectively, the data
report for the first time on the role
of UQCRB as a key component in the mitochondrial Complex
III as an oxygen sensor and the mode of action of terpestacin at
the molecular level (Fig. 7H).
Terpestacin Modulates the O2-Sensing Function of Complex
III by Targeting UQCRB without Acting as a Respiratory Poi-
son—Utilizing the Q-cycle, Complex III (cytochrome bc1 com-
plex) transfers electrons from ubiquinol to cytochrome c and
contributes to the generation of an electrochemical proton gra-
dient (23–25). Two electrons from the oxidation of ubiquinol
are conveyed to the high and low potential redox chains com-
prising the Rieske iron-sulfur cluster and c1 heme and the bL
and bH hemes, respectively (23). After the first electron is trans-
ferred to the Rieske iron-sulfur cluster, a semiquinone (SQ)
radical intermediate in the Qo site of cytochrome b (intermem-
brane space side of the mitochondrial inner membrane)
donates the second electron to the low potential chain. Such
efficient splitting of electrons between the high and low poten-
tial chains allows complex III to serve a role in energy transduc-
tion without deleterious side reactions, but when the bifur-
cation reaction is partially blocked, the SQ intermediate is likely
to give an electron to O2, resulting in the formation of superox-
ide (26, 27). Intriguingly, although the generation of ROSby any
mechanism is an O2-dependent process, an increase in mito-
chondrial ROS at lower O2 levels (1–5% O2) in intact cells sug-
gests that during hypoxia, the lifetime of SQmay be prolonged,
thereby promoting ROS generation (26), which is released into
FIGURE 6. Effect of terpestacin on tumor angiogenesis in vivo. Mice bearing FM3A breast tumors were
treated with saline (control) or terpestacin (Ter, one-third of LD50, LD50  7.5 M). A, time course of dynamic
contrast-enhanced magnetic resonance signal intensity change associated with neovasculature. ##, p	 0.01
versus saline control. B, immunohistochemistry of tumor vasculature in paraffin sections of tumor tissues was
performed using an antibody against the vascular antigen CD34. The microvessel density of control tumor
tissueswas defined as 100%. *,p	 0.001 versus saline control.C, effect of terpestacin on expressionof hypoxia-
responsible genes in murine tumor angiogenesis model. Tumor sections treated with saline (left panels) or
terpestacin (right panels) were immunostainedby antibodies against CD34 (top panels), HIF-1 (middle panels),
and VEGF (bottom panels), respectively. D, effect of terpestacin on VEGF expression in mouse xenografts. The
concentration of VEGF protein in tumor tissue extracts was determined by a VEGF-enzyme-linked immunosor-
bent assay. ††, p	 0.05 versus saline control.
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the intermembrane space (28, 29) and may be involved in cel-
lular signaling. This can be further supported by the notion that
complex III-linked ROS production is mainly regulated by the
redox state of the ubiquinone pool (30).
First, to investigate whether Complex III can produce ROS
during hypoxia, we and other groups confirmed thatmyxothia-
zol and stigmatellin inhibit not only hypoxia-induced ROS for-
mation but also hypoxia-induced HIF-1 stabilization (3) as
shown in supplemental Fig. S3, but these small molecules do
not bind to UQCRB as shown in Fig. 2A. Unlike the Qo site
inhibitors that prevent the formation of SQ by blocking the
electron entry into Complex III and thereby blocking mito-
chondrial respiration and ATP generation, terpestacin sup-
presses hypoxia-induced ROS generation without inhibiting
mitochondrial respiration, as confirmed by a mitochondrial
oxygen consumption assay (Fig. 4B). Indeed, our present study
including in vitro and in vivo experiments was performed at
optimum doses of terpestacin with no cytotoxicity. Second, we
also observed that terpestacin did not compete with antimycin
for binding to theQi site of Complex III (Fig. 2A). Furthermore,
terpestacin significantly decreased hypoxia-induced ROS
production even in the presence of antimycin as shown in
supplemental Fig. S4, indicating that binding of terpestacin to
UQCRB might play an important role in modulating ROS pro-
duction during hypoxia.
According to the three-dimensional structure of Complex III
(20, 31, 32), UQCRB is a 13.4-kDa protein that resides at the
bottom of cytochrome bwhere the heme bH andQi site exist on
the n side of the inner membrane (Fig. 3A). Our docking mod-
eling reveals that terpestacin binds to the interface of the bind-
ing site between UQCRB and cytochrome b, which was con-
firmed through UQCRB mutagenesis studies (Fig. 3C). In light
of this, we suggest that UQCRB may play an important role in
mitochondrial ROS generation by modulating electron flux
FIGURE7.RoleofUQCRB inangiogenesis.A, effect ofUQCRBoverexpressionon tumor cell invasion. ###,p	0.007 versus control (Con). The results shownare
representativeof three independentexperiments.B, effect ofUQCRBoverexpressiononmitochondrial ROSgeneration inHT1080cells treatedwith terpestacin
(20 and40M), antimycinA (10M), or radicicol (5M). *,p	0.001 versus control; †,p	0.006 versusUQCRBoverexpression. Each value represents themean
S.E. from three independent experiments.DCF, 2,7-dichlorofluorescein;Neo, control vector.C, effect of UQCRBoverexpression onHIF-1protein levels under
normal oxygen conditions. CoCl2 (100M) was used as a positive control. The results shown are representative of three independent experiments.D, effect of
UQCRB overexpression on VEGF mRNA levels. The results shown are representative of three independent experiments. E, reverse transcription-PCR analysis
shows the significant knockdown of UQCRB mRNA by siRNA. The results shown are representative of three independent experiments. F, effects of siRNA
knockdown of UQCRB on the protein levels of HIF-1 and VEGF under hypoxia. The results shown are representative of three independent experiments.
G, effect of UQCRB knockdown on the angiogenesis-promoting activity of HT1080 cells during hypoxia. Conditioned media (CM) from HT1080 cells in each
culture conditionwere used for the endothelial cell invasion (upper panel) and tube formation (lower panel) assays. The results shownare representative of two
independent experiments.H, themodel indicates that UQCRB is a crucial component of amitochondrial O2 sensor in Complex III and that terpestacin binding
to UQCRB inhibits the hypoxic signal transduction sequence by attenuating hypoxia-induced ROS generation, HIF-1 synthesis and stabilization, expression
of VEGF, and thus tumor angiogenesis. PHD, prolyl hydroxylase.
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through cytochrome b, thereby influencing the lifetime of the
semiquinone at the Qo site. When bound to Complex III, terp-
estacin seems to accelerate the forward electron transfer to the
cytochrome b, which shortens the lifetime of SQ at the Qo site
to attenuate hypoxia-induced ROS production without block-
ing mitochondrial respiration. Therefore, we propose that dur-
ing hypoxia, terpestacin bound to UQCRB of Complex III may
mimic a condition where partially oxidized ubiquinone pool
slows down the forward electron transfer to induce a reverse
electron transfer onto O2 by reduced heme bL, resulting in the
prolonged lifetime of SQ at the Qo pocket, thereby enhancing
the probability of superoxide production as was the case with
antimycin-induced ROS production (23, 30). In addition,
recent evidence has revealed that the membrane potential
enhances the formation of superoxide from Complex III by
opposing electron transfer fromheme bL to bH (33). Indeed, the
binding of terpestacin to UQCRB decreases the mitochondrial
membrane potential as shown in Fig. 4A, suggesting that the
inhibition of ROS generation by terpestacin might correlate
with the loweredmembrane potential.We have also confirmed
that the decrease of mitochondrial membrane potential by ter-
pestacin treatment is not associated with the disruption of the
functional structure of Complex III, because terpestacin bind-
ing to UQCRB did not cause the dissociation of the subunit
from Complex III (supplemental Fig. S5). Nonetheless, we still
cannot exclude the possibility that terpestacin could interact
directly with ROS released to the matrix or to the intermem-
brane space, but in either case it is clear that terpestacin renders
Complx III incapable of transducing hypoxia into anROS signal
that mediates protective responses in the cell.
Terpestacin Provides a Unique Tool to Regulate Tumor Pro-
gression by Acting at the Cellular Oxygen Sensor—Our findings
indicate that UQCRB performs two independent functions
related to (a) electron transport at Complex III and (b) mediat-
ing cellular O2 sensing bymodulating ROS production at Com-
plex III in response to hypoxia. UQCRB is known to play a
pivotal role in the assembly and maintenance of Complex III,
which is conserved in the respiratory chain of all aerobic orga-
nisms as well as in the electron transfer systems of chloroplasts
and photosynthetic bacteria (34, 35). Hereditary defects in the
UQCRB gene cause several mitochondrial diseases such as
hypoglycemia, lactic acidosis, myopathy, and cardiomyopathy
(36, 37), which are partially associated with deregulation of
angiogenesis (38, 39). These diverse phenotypes may arise
because various genetic mutations could differentially affect
the two functions of UQCRB, namely electron transfer/bioen-
ergetics and/or O2-sensing functions of mitochondria. It is also
noteworthy that UQCRB recently turned out to be overex-
pressed in 218 hepatocellular carcinoma specimens from a
microarray study, implying that the gene plays a significant role
in tumorigenesis (40). Accordingly, the small molecule terpes-
tacin may serve as a unique and reversible tool for regulating
UQCRB function in regard to O2 sensing, without affecting
expression levels of the protein. Furthermore, it represents a
potential landmark in the development of new anti-angiogenic
drugs targeting the mitochondrial O2 sensor. Although myx-
othiazol and stigmatellin also block hypoxia-induced ROS sig-
naling, the toxicity resulting from inhibition of the electron
transport chain renders these and similar compounds useless as
clinical tools. Conceptually, a drug that interferes with the abil-
ity of cells to detect and signal hypoxia without inhibiting res-
piration would be ideal as an anti-tumor agent because it would
undermine the ability to activateHIF-mediated transcription in
the tumor cells. In addition to mediating the angiogenesis
response, HIF regulates the expression of a diverse set of genes
that participate in cell proliferation, cell migration, and cell sur-
vival under conditions of hypoxic stress. These functions all
contribute to tumor survival and progression, and excessive
HIF activation has been correlated with poor clinical prognosis
in a number of different types of cancer (41, 42). The ability of
terpestacin to suppress tumor angiogenesis in vivo without
apparent systemic toxicity underscores its potential utility, or
that of its derivatives, as a new anticancer agent targeting
UQCRB that plays a key role as the mitochondrial O2 sensor.
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